A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(4 sites)

Norway

Oslo University Hospital HF, Oslo

Sweden

Sahlgrenska University Hospital, Gothenburg

Skåne University Hospital, Lund

Karolinska Universitetssjukhuset, Stockholm